Genomic Health Inc. (NASDAQ:GHDX) insider Steven Shak sold 5,000 shares of Genomic Health stock in a transaction that occurred on Tuesday, October 11th. The shares were sold at an average price of $30.39, for a total transaction of $151,950.00. Following the transaction, the insider now directly owns 332,207 shares of the company’s stock, valued at $10,095,770.73. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Steven Shak also recently made the following trade(s):

  • On Tuesday, September 13th, Steven Shak sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $26.83, for a total transaction of $134,150.00.
  • On Tuesday, August 23rd, Steven Shak sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $27.24, for a total transaction of $136,200.00.
  • On Tuesday, July 19th, Steven Shak sold 5,000 shares of Genomic Health stock. The shares were sold at an average price of $27.42, for a total transaction of $137,100.00.

Shares of Genomic Health Inc. (NASDAQ:GHDX) traded down 5.15% during midday trading on Wednesday, reaching $28.91. 215,779 shares of the company’s stock traded hands. The company’s market capitalization is $964.03 million. The stock’s 50 day moving average is $28.21 and its 200-day moving average is $27.28. Genomic Health Inc. has a 52 week low of $20.05 and a 52 week high of $35.79.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). The firm earned $81.97 million during the quarter, compared to analysts’ expectations of $81.27 million. Genomic Health had a negative return on equity of 21.02% and a negative net margin of 8.84%. The firm’s quarterly revenue was up 16.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.29) EPS. On average, analysts forecast that Genomic Health Inc. will post ($0.47) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

GHDX has been the subject of several recent research reports. Leerink Swann reaffirmed a “buy” rating on shares of Genomic Health in a report on Tuesday, June 21st. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, July 5th. Bank of America Corp. set a $28.00 price target on shares of Genomic Health and gave the stock a “sell” rating in a report on Wednesday, August 3rd. Canaccord Genuity reissued a “buy” rating and issued a $38.00 price target on shares of Genomic Health in a report on Friday, August 5th. Finally, Jefferies Group boosted their price target on shares of Genomic Health from $25.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, August 17th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $32.50.

A number of hedge funds have recently bought and sold shares of the company. Independent Portfolio Consultants Inc. boosted its stake in Genomic Health by 54.5% in the second quarter. Independent Portfolio Consultants Inc. now owns 17,595 shares of the company’s stock worth $456,000 after buying an additional 6,210 shares in the last quarter. Royal Bank of Canada boosted its stake in Genomic Health by 6,543.0% in the first quarter. Royal Bank of Canada now owns 8,503 shares of the company’s stock worth $210,000 after buying an additional 8,375 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Genomic Health by 54.0% in the first quarter. Renaissance Technologies LLC now owns 446,021 shares of the company’s stock worth $11,048,000 after buying an additional 156,421 shares in the last quarter. HBK Investments L P bought a new stake in Genomic Health during the first quarter worth approximately $886,000. Finally, Kimelman & Baird LLC boosted its stake in Genomic Health by 2.3% in the first quarter. Kimelman & Baird LLC now owns 21,940 shares of the company’s stock worth $543,000 after buying an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 88.92% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

5 Day Chart for NASDAQ:GHDX

Receive News & Stock Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related stocks with our FREE daily email newsletter.